Translational Neuroscience Optimization of GlyT1 Inhibitor
What is the purpose of this trial?
This study involves an interlinked design to determine the dose associated with optimal activity and occupancy of the Glyt1I PF-03463275 in healthy subjects and schizophrenia subjects and to test this dose in combination with cognitive remediation in the treatment of cognitive impairments of Schizophrenia.
- 21 Years - 55 Years
- National Institutes of Health
- Last Updated:
- Study HIC#: